Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19

Simple item page
dc.contributor.authorSánchez, Andrés
dc.contributor.authorAlape-Girón, Alberto
dc.contributor.authorMoreira-Soto, Andrés
dc.contributor.authorArguedas, Mauricio
dc.contributor.authorBrenes, Hebleen
dc.contributor.authorBuján, Willem
dc.contributor.authorCorrales-Aguilar, Eugenia
dc.contributor.authorDíaz, Cecilia
dc.contributor.authorEcheverri, Ann
dc.contributor.authorFlores-Díaz, Marietta
dc.contributor.authorGómez, Aarón
dc.contributor.authorHernández, Andrés
dc.contributor.authorHerrera, María
dc.contributor.authorLeón, Guillermo
dc.contributor.authorMacaya, Román
dc.contributor.authorMolina-Mora, José Arturo
dc.contributor.authorMora, Javier
dc.contributor.authorNarayanan, Aarthi
dc.contributor.authorSanabria, Alfredo
dc.contributor.authorSánchez, Laura
dc.contributor.authorSegura, Álvaro
dc.contributor.authorSegura, Eduardo
dc.contributor.authorSolano, Daniela
dc.contributor.authorSoto, Claudio
dc.contributor.authorStynoski, Jennifer L
dc.contributor.authorVargas, Mariángela
dc.contributor.authorVillalta, Mauren
dc.contributor.authorDrexler, Jan Felix
dc.contributor.authorGutiérrez, José María
dc.date.accessioned2025-07-09T20:43:49Z
dc.date.available2025-07-09T20:43:49Z
dc.date.issued2021-09
dc.descriptionARTICULO
dc.description.abstractThe emergence and dissemination of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the resulting COVID-19 pandemic triggered a global public health crisis. Although several SARS-CoV-2 vaccines have been developed, demand far exceeds supply, access to them is inequitable, and thus, populations in low- and middle-income countries are unlikely to be protected soon (1). Furthermore, there are no specific therapies available, which is a challenge for COVID-19 patient care (2). Thus, the appearance of SARS-CoV-2 variants and reports of reinfections associated with immune escape (3, 4) highlight the urgent need for effective and broad coverage COVID-19 therapeutics
dc.description.sponsorshipLos autores
dc.identifier.otherdoi: 10.3389/fmed.2021.743325
dc.identifier.urihttp://hdl.handle.net/20.500.11764/4907
dc.language.isoen
dc.publisherLos autores
dc.relation.ispartofseriesFrontiers in Medicine; v.8 set. 2021: Article 743325
dc.subjectCOVID-19
dc.subjectINMUNOTERAPIA
dc.titleHeterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
21 Heterologous_Hyperimmune_Polyclonal_Antibodies_Aga.pdf
Size:
384.15 KB
Format:
Adobe Portable Document Format
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
85 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Investigaciones en la CCSS